OncoMatch/Clinical Trials/NCT06533761
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Is NCT06533761 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Eganelisib and Eganelisib in combination with cytarabine for aml, adult.
Treatment: Eganelisib · Eganelisib in combination with cytarabine — This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) or r/r higher-risk myelodysplastic syndromes (HR-MDS). The study consists of 2 parts: * Part 1: Dose Escalation (DE) in both monotherapy and in combination. * Part 2: Dose Optimization
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: stem cell transplant
Exception: allowed if >6 months prior to Cycle 1 Day 1
Autologous or allogeneic stem cell transplant within 6 months prior to Cycle 1 Day 1
Lab requirements
Kidney function
Adequate renal function measured within 7 days prior to the first dose of eganelisib
Liver function
Adequate hepatic function measured within 7 days prior to the first dose of eganelisib
Adequate hepatic and renal function measured within 7 days prior to the first dose of eganelisib
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Anshutz Cancer Pavilion · Aurora, Colorado
- Moffitt Cancer Center · Tampa, Florida
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Washington University in St Louis · St Louis, Missouri
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06533761 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify